Tianjin Development Holdings Ltd. (TIANJIN DEV) has disclosed the 2025 audited results of its 34.12%-owned Shenzhen-listed subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd. (Lisheng Pharmaceutical).
Revenue and Earnings • Operating income reached RMB1.39 billion, a 4.18% year-on-year increase. • Net profit jumped to RMB422.73 million, up 127.24% from 2024, driven by a three-fold surge in investment income to RMB324.77 million. • Net profit attributable to the parent company climbed 125.55% to RMB416.28 million. • Basic and diluted EPS doubled to RMB1.62 from RMB0.72.
Cost Structure and Profitability • Cost of sales rose 3.74% to RMB622.79 million, keeping the gross margin broadly stable at 55.3% (2024: 55.1%). • Total operating costs increased only 2.13%, aided by an 8.97% reduction in research expenses to RMB115.19 million and a deeper finance-income surplus of RMB48.64 million. • Operating profit more than doubled to RMB469.13 million, reflecting efficient cost control and higher investment returns.
Balance Sheet Highlights • Total assets stood at RMB5.58 billion, down 3.47% from end-2024, mainly due to a 17.27% contraction in non-current assets. • Total liabilities declined 6.27% to RMB923.86 million, lowering the gearing profile. • Equity attributable to shareholders fell 2.97% to RMB4.63 billion, as a RMB412.44 million negative swing in other comprehensive income offset retained-earnings growth. • Return on average equity (attributable) improved to roughly 9%, compared with about 4% in 2024.
Dividend and Capitalisation Proposal The board of Lisheng Pharmaceutical proposes: 1. Cash dividend of RMB6.00 (tax-inclusive) for every 10 shares—equivalent to RMB0.60 per share—based on 256.89 million outstanding shares after deducting treasury stock. The total distribution would approximate RMB154.13 million. 2. Capitalisation of reserves to issue 2 bonus shares for every 10 shares (20% stock dividend).
The proposal is subject to approval at Lisheng Pharmaceutical’s 2025 AGM. Based on its 34.12% stake, TIANJIN DEV would be entitled to an estimated RMB52.64 million in cash dividends and proportional bonus shares upon approval.
Other Comprehensive Income Fair-value changes in equity instruments resulted in a negative RMB408.10 million impact, contributing to total other comprehensive loss of RMB412.44 million.
Share Capital Movements • Share capital was marginally lower at 257.59 million shares due to repurchases, while treasury shares increased to 85.77 million. • Capital reserves declined 1.82% to RMB1.62 billion, partly reflecting the proposed bonus-share issue.
Key Takeaways Lisheng Pharmaceutical delivered strong earnings growth in 2025 on modest revenue expansion, underpinned by higher investment income and consistent cost discipline. Despite a large mark-to-market hit on equity investments, the company’s robust profitability supported a higher dividend payout and a share bonus, signalling confidence in future cash-flow generation. The results are expected to contribute positively to TIANJIN DEV’s consolidated performance once the subsidiary’s distribution is finalized.
Comments